Skip to main content
DYAI
NASDAQ Life Sciences

Dyadic 10-Q: Going Concern Reaffirmed, Cash Funds Operations Only ~7 Months

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.327
Mkt Cap
$13.101M
52W Low
$0.315
52W High
$1.6
52W Position info
3.8% above low
Off High info
80% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

DYAI is trading near its 52-week low of $0.315 (3.8% above the low).

Summary

Dyadic's Q3 10-Q reaffirms substantial doubt about going concern: $4.57 million of unrestricted cash covers only about seven months, and a lock-up through December 17, 2026 plus an expired shelf block new equity sales. Q3 revenue fell 61.4% to $449,101.


Key Events · Earnings and Guidance · DYAI

  • Going Concern Doubt Reaffirmed

    Management concluded substantial doubt exists about the ability to continue as a going concern within one year of the November 13, 2026 issuance date, and said the August 2026 offering proceeds do not alleviate that doubt.

  • Cash Runway Roughly Seven Months

    Unrestricted cash, cash equivalents and investments of $4.57 million, against average operating cash use of about $0.59 million per month, are expected to fund operations for approximately seven months — less than twelve.

  • Capital Raise Blocked Until December 17

    The August 2026 offering's securities purchase agreement prohibits new equity issuance until December 17, 2026, and the Form S-3 shelf expired August 25, 2026, so the $4,238,000 ATM cannot be used; after that date baby-shelf limits apply while public float stays below $75 million.

  • Nasdaq Deficiencies, March 2027 Deadline

    Nasdaq notices dated September 25, 2026 flag the $1.00 minimum bid price and $35 million market value of listed securities shortfalls, with a compliance period ending March 24, 2027; the company also fails the stockholders' equity requirement.


Analysis · DYAI · Life Sciences

The survival math is now explicit in Dyadic's Q3 10-Q: unrestricted cash, equivalents and investments of $4.57 million are expected to fund operations for roughly seven months, well short of the twelve-month going-concern window, and management says the August 2026 offering proceeds do not alleviate the doubt. Selling stock to plug the gap is not an option — the August offering's securities purchase agreement bars new equity issuance until December 17, 2026, and the Form S-3 shelf expired August 25, 2026, leaving the ATM unusable. Layered on top are Nasdaq bid-price and market-value deficiencies with a March 24, 2027 compliance deadline and $5.09 million of 8% convertible notes maturing December 31, 2027, $2.09 million of which is held by CEO Mark Emalfarb's family trusts. Revenue fell 61.4% to $449,101 in the quarter as grant and collaboration work wound down, so the first direct product sales are not yet close to covering the roughly $0.59 million monthly cash burn.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYAI was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $0.32 to $1.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYAI - Latest Insights

DYAI
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.3501
Real-time Price: $0.327 info
Change: -$0.0231 (-7%) info
Market Cap: $13.101M info
DYAI
Sep 25, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4198
Real-time Price: $0.327 info
Change: -$0.0928 (-22%) info
Market Cap: $13.101M info
DYAI
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $0.327 info
Change: -$0.383 (-54%) info
Market Cap: $13.101M info
DYAI
Aug 14, 2026, 9:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7702
Real-time Price: $0.327 info
Change: -$0.4432 (-58%) info
Market Cap: $13.101M info
DYAI
Aug 13, 2026, 5:25 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.7854
Real-time Price: $0.327 info
Change: -$0.4584 (-58%) info
Market Cap: $13.101M info